Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials

Over the last two decades, several epi‐drugs, immune checkpoint inhibitors (ICIs) and adoptive cell therapies have received clinical approval for use in certain types of cancer. However, monotherapy with epi‐drugs or ICIs has shown limited efficacy in most cancer patients. Epigenetic agents have been shown to regulate the crosstalk between the tumor and host immunity to alleviate immune evasion, suggesting that epi‐drugs can potentially synergize with immunotherapy. In this review, we discuss recent insights into the rationales of incorporating epigenetic therapy into immunotherapy, called epi‐immunotherapy, and focus on an update of current clinical trials in both hematological and solid malignancies. Furthermore, we outline the future challenges and strategies in the field of cancer epi‐immunotherapy.

• Publication year

  2022

• Venue

  Cancer Communications

• Publication date

  2022-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cac2.12313PMID 35642676PMCID 9198339
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials

  2022cited by this paper
• Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial

  2021cited by this paper
• The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation

  2021cited by this paper
• Entinostat induces antitumor immune responses through immune editing of tumor neoantigens.

  2021cited by this paper
• Safety and efficacy of chidamide in combination with decitabine plus anti-PD-1 camrelizumab after relapse or progression on decitabine-plus-camrelizumab in classical Hodgkin lymphoma.

  2021cited by this paper
• Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

  2021cited by this paper
• EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner

  2021cited by this paper
• Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

  2021cited by this paper
• Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis

  2021cited by this paper
• CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia

  2021cited by this paper
• A PHASE II STUDY OF ANTI‐PD‐1 SINTILIMAB IN COMBINATION WITH CHIDAMIDE AND AZACITIDINE IN REFRACTORY AND RELAPSED PERIPHERAL T‐CELL LYMPHOMA

  2021cited by this paper
• The promise and perils of immunotherapy.

  2021cited by this paper
• DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells.

  2021cited by this paper
• Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations

  2021cited by this paper
• Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

  2021cited by this paper
• Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

  2021cited by this paper
• Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

  2021cited by this paper
• Phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer Big Ten Cancer Research Consortium BTCRC GU16-043.

  2021cited by this paper
• Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming

  2021cited by this paper
• Epigenetic strategies to boost CAR T cell therapy.

  2021cited by this paper
• Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

  2021cited by this paper
• Emerging agents and regimens for AML

  2021cited by this paper
• Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy

  2021cited by this paper
• Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy

  2021cited by this paper
• Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis

  2021cited by this paper
• A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint

  2021cited by this paper
• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

  2021cited by this paper
• Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).

  2021cited by this paper
• Targeting macrophages in cancer immunotherapy

  2021cited by this paper
• Transient “rest” restores functionality in exhausted CAR-T cells via epigenetic remodeling

  2021cited by this paper
• Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance

  2021cited by this paper
• A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma

  2021influential reference
• MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study

  2021cited by this paper
• Endogenous retroviruses in the origins and treatment of cancer

  2021cited by this paper
• T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments

  2021cited by this paper
• EZH2: a novel target for cancer treatment

  2020cited by this paper
• HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

  2020cited by this paper
• Unraveling exhaustion in adaptive and conventional NK cells

  2020cited by this paper
• Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

  2020cited by this paper
• Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy.

  2020cited by this paper
• Cancer Epigenetics, Tumor Immunity, and Immunotherapy.

  2020cited by this paper
• Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells

  2020cited by this paper
• Tazemetostat: First Approval

  2020cited by this paper
• Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression

  2020cited by this paper
• Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy.

  2020cited by this paper
• Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.

  2020cited by this paper
• An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

  2020cited by this paper
• Limited-duration anti-PD-1 therapy for patients with metastatic melanoma

  2020cited by this paper
• Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).

  2020cited by this paper
• Top 10 Challenges in Cancer Immunotherapy.

  2020cited by this paper
• Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

  2020cited by this paper
• Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

  2020cited by this paper
• Gene regulation by long non-coding RNAs and its biological functions

  2020cited by this paper
• PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation

  2020cited by this paper
• Checkpoint inhibitor immunotherapy in kidney cancer

  2020cited by this paper
• A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer

  2020cited by this paper
• Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

  2020cited by this paper
• Abstract PO-007: The Class I/IV HDAC Inhibitor Mocetinostat Augments Anti-Tumor Immune Responses in Melanoma Patients

  2020cited by this paper
• Abstract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors

  2020cited by this paper
• Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).

  2020cited by this paper
• Immune escape and immunotherapy of acute myeloid leukemia.

  2020cited by this paper
• Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

  2020cited by this paper
• Targeting the epigenetic regulation of antitumour immunity

  2020cited by this paper
• Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

  2020cited by this paper
• Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma.

  2020cited by this paper
• Targeting immune checkpoints in hematological malignancies

  2020cited by this paper
• Abstract CT160: The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma

  2020cited by this paper
• Biomarker-driven management strategies for peripheral T cell lymphoma

  2020cited by this paper
• Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer.

  2020cited by this paper
• Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia

  2020cited by this paper
• Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors

  2020cited by this paper
• Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4).

  2020cited by this paper
• A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer

  2020influential reference
• Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells

  2020cited by this paper
• HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer

  2020cited by this paper
• Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL).

  2020cited by this paper
• Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer

  2020cited by this paper
• Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

  2020cited by this paper
• Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors

  2020cited by this paper
• Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer

  2020cited by this paper
• Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma

  2020cited by this paper
• Combinations take centre stage in PD1/PDL1 inhibitor clinical trials

  2020cited by this paper
• A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia

  2020cited by this paper
• A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)

  2020cited by this paper
• A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

  2019cited by this paper
• Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

  2019cited by this paper
• Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

  2019cited by this paper
• Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

  2019cited by this paper
• Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma

  2019cited by this paper
• Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).

  2019cited by this paper
• Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

  2019cited by this paper
• Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

  2019cited by this paper
• Epidrugs: targeting epigenetic marks in cancer treatment

  2019cited by this paper
• Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

  2019cited by this paper
• SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION WITH TAZEMETOSTAT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B STUDY

  2019cited by this paper
• Immunotherapy of Melanoma: Facts and Hopes

  2019cited by this paper
• HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti–PD-L1 Therapy

  2019cited by this paper
• The emerging role of epigenetic therapeutics in immuno-oncology

  2019cited by this paper
• Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine

  2019influential reference
• Biology and therapy of primary mediastinal B‐cell lymphoma: current status and future directions

  2019cited by this paper

• Harnessing epigenetic inhibitors: A promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment.

  2025cites this paper
• Dual effect of targeting LSD1 on the invasiveness and the mechanical response of acute lymphoblastic leukemia cells.

  2025cites this paper
• Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma

  2025cites this paper
• Comparative epigenomics to clinical trials in human breast cancer and canine mammary tumor

  2025cites this paper
• Smart on-demand drug release strategies for cancer combination therapy.

  2025cites this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cites this paper
• Epigenetically targeting PRMT5 promotes antitumor immunity by inducing endogenous retroviruses expression and triggering viral mimicry response.

  2025cites this paper
• Targeting epigenetic modifications as an emerging immunotherapeutic strategy for cancers

  2025cites this paper
• Epigenetic modulation with nanosatellite triggers tumoricidal immunity for hepatocellular carcinoma treatment

  2025cites this paper
• Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies

  2025cites this paper
• Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies

  2025cites this paper
• Immunotherapy in cancer: novel approaches and future perspectives

  2025cites this paper
• Molecular mastery: Harnessing DNA technology for disease prevention

  2025cites this paper
• Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

  2025cites this paper
• Furamidine, a methyltransferase inhibitor, is a potential anti-Babesia spp. chemotherapeutic

  2025cites this paper
• Nuevas terapias en hematología

  2025cites this paper
• Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances

  2025cites this paper
• A systematic review of progress toward unlocking the power of epigenetics in breast cancer: latest updates and perspectives

  2025cites this paper
• Hepatocellular carcinoma epi-immunotherapy with polyion complex micelles co-delivering HDAC8 inhibitor and PD-L1 siRNA

  2024cites this paper
• Epigenetic small-molecule screen for inhibition and reversal of acinar ductal metaplasia in mouse pancreatic organoids

  2024cites this paper
• Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review

  2024cites this paper
• Alteration in DNA methylation patterns: Epigenetic signatures in gastrointestinal cancers.

  2024cites this paper
• Epigenetic Modulations in Triple-Negative Breast Cancer: Therapeutic Implications for Tumor Microenvironment.

  2024cites this paper
• Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives

  2024cites this paper
• Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.

  2024cites this paper
• Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature

  2023cites this paper
• Epigenetic Small-Molecule Screen for Inhibition and Reversal of Acinar Ductal Metaplasia in Mouse Pancreatic Organoids

  2023cites this paper
• Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer.

  2023cites this paper
• DNA methylation-based depiction of the immune microenvironment and immune-associated long non-coding RNAs in oral cavity squamous cell carcinomas.

  2023cites this paper
• CXXC finger protein 1 (CFP1) bridges the reshaping of genomic H3K4me3 signature to the advancement of lung adenocarcinoma

  2023cites this paper
• Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

  2023cites this paper
• Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy

  2023cites this paper
• Novel insights into cancer stem cells targeting: CAR-T therapy and epigenetic drugs as new pillars in cancer treatment

  2023cites this paper
• Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer

  2023cites this paper
• Epigenetic Regulation in Breast Cancer: Insights on Epidrugs

  2023cites this paper
• Epigenetic reprogramming in cancer: From diagnosis to treatment

  2023cites this paper
• Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials

  2022cites this paper